Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZLAB vs XENE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XENE Captures Overall Composite Edge (33.3 SELL vs 47.4 HOLD), While ZLAB Leads 4–2 on Growth & Valuation Pillars

XENE Overall Winner 6-Pillar Tally: ZLAB 4 – 2 XENE Matrix Metrics: ZLAB 4 – 4 XENE

As of Nov 16, 2026, Xenon Pharmaceuticals Inc (XENE) captures the overall head-to-head institutional edge over Zai Lab Limited (ZLAB) on higher Unified Composite conviction (33.3/100 SELL vs. 47.4/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while ZLAB wins 4–2 across the 6-pillar growth and valuation breakdown. ZLAB trades at $23.83 (N/M Forward P/E, -63.0% operating margin) versus XENE at $39.30 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. XENE 33.3/100 SELL), XENE captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -63.0% operating margin) and revenue trajectory (-100.0% vs. -6.8% YoY).
  • Technical & Structure Timing Caution: ZLAB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.1); meanwhile XENE is in a Breakdown options structure phase (RSI 51.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZLAB vs XENE
ZLAB NASDAQ
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.83
-3.13% 1D
Market Cap $3.0B
TTM Revenue $442M
Forward P/E N/M
Beta / 30D Vol 1.19β · 78% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 53.5
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.1 · SMA20: $23.97 · SMA50: $24.57
XENE NASDAQ Head-to-Head Winner
Xenon Pharmaceuticals Inc
Pharmaceutical Preparations
$39.30
-2.9% 1D
Market Cap $4.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.70β · 36% Vol
Unified Composite Score
33.3 / 100 SELL
Tech 15.0 Fund 44.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 51.2 · SMA20: $38.20 · SMA50: $40.73

6-Pillar Scorecard Institutional Category Breakdown (ZLAB 4 – 2 XENE)

Columns: Metric · ZLAB · XENE
1. Valuation Multiples ZLAB
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 6.8x N/M
2. Growth & Scale ZLAB
Revenue Growth (YoY) -6.8% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $442M N/A
Market Cap $3.0B $4.0B
3. Profitability & Quality XENE
Gross Margin 0.6% N/A
Operating Margin -63.0% 0.0%
Net Profit Margin -44.9% 0.0%
Return on Equity (ROE) -30.0% -50.3%
4. Balance Sheet & Cash Flow ZLAB
Cash Generation (TTM) -$262M EBITDA -$357M
Cash Flow Margin -59.3% EBITDA Mgn N/A
Net Cash / Leverage $5.01 Book/Sh · -30.0% ROE $77M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XENE
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 58.4% (58th %ile) 57.6% (14th %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat ZLAB
OpEx & R&D Intensity 63.6% of Rev ($281M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZLAB (4) vs XENE (4)
Institutional Metric ZLAB XENE Criterion Row Edge
Market Capitalization
Scale
$3.0B $4.0B Larger Scale XENE
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-6.8% -100.0% Higher Growth ZLAB
Operating Margin (TTM)
Profitability
-63.0% 0.0% Higher Margin XENE
Net Profit Margin
Profitability
-44.9% 0.0% Higher Margin XENE
Return on Equity (ROE)
Capital Efficiency
-30.0% -50.3% Higher ROE ZLAB
52-Week Range Position
Momentum
60% ($16–$29) 15% ($33–$73) Stronger Trend ZLAB
Beta / 30D Volatility
Risk Regime
1.19β · 78% Vol 0.70β · 36% Vol Lower Realized Risk XENE
Unified Institutional Score
Composite Signal
47.4 / 100 (HOLD) 33.3 / 100 (SELL) Higher Composite ZLAB
Trailing 12M Revenue (USD)
Operating Scale
$442M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$262M EBITDA ($5.01 Book/Sh · -30.0% ROE) -$357M ($77M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XENE +14.6 pp
ZLAB: +2.76% · XENE: +17.36%
3M Horizon ZLAB +30.99 pp
ZLAB: -6.8% · XENE: -37.79%
6M Horizon ZLAB +53.17 pp
ZLAB: +26.35% · XENE: -26.82%
1Y Horizon ZLAB +11.5 pp
ZLAB: +9.66% · XENE: -1.84%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs XENE. Trailing 12-month operating profitability (ZLAB -63.0% vs XENE 0.0%) and valuation multiples (ZLAB N/M vs XENE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ZLAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$442M
Gross Margin0.6%
Op. Margin-63.0%
ROE / Fwd P/E-30.0% · N/M
XENE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-50.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZLAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 58.4%
IV Percentile 58th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZLAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XENE BREAKDOWN
175d in phase · OBV ACCUMULATION
Current IV 57.6%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact XENE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZLAB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and -63.0% operating margin.
OpEx & R&D Reinvestment 63.6% of Rev ($281M)
90D Engineering Disclosures 0 Published
XENE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ZLAB vs XENE Key Questions & Quantitative Answers

As of Nov 16, 2026, Xenon Pharmaceuticals Inc (XENE) captures the overall head-to-head institutional edge over Zai Lab Limited (ZLAB) on higher Unified Composite conviction (33.3/100 SELL vs. 47.4/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while ZLAB wins 4–2 across the 6-pillar growth and valuation breakdown. ZLAB trades at $23.83 (N/M Forward P/E, -63.0% operating margin) versus XENE at $39.30 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. XENE 33.3/100 SELL), XENE captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -63.0% operating margin) and revenue trajectory (-100.0% vs. -6.8% YoY). Technical & Structure Timing Caution: ZLAB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.1); meanwhile XENE is in a Breakdown options structure phase (RSI 51.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ZLAB leads the Growth & Scale pillar: ZLAB posts -6.8% YoY revenue growth and +0.0% YoY earnings growth on $442M TTM revenue (0.6% gross margin, -63.0% operating margin), compared with XENE at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ZLAB generates $442M in USD-normalized revenue versus N/A for XENE. In operating R&D and SG&A reinvestment, ZLAB deploys 63.6% of Rev ($281M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XENE.

ZLAB screens cheaper on headline valuation multiples. ZLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-59.3% EBITDA margin), whereas XENE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZLAB (-30.0% ROE) versus XENE (-50.3% ROE) capital efficiency.

In options market volatility and institutional positioning, ZLAB carries 58.4% implied volatility (58th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 78% Vol realized risk). By comparison, XENE carries 57.6% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.70β · 36% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.